Dyskinesia
FECO (Full Extract Cannabis Oil) has become a primary area of interest for managing Dyskinesia, specifically Levodopa-Induced Dyskinesia (LID) in Parkinson’s disease and Tardive Dyskinesia (TD) caused by long-term antipsychotic use.
Dyskinesia is essentially a "communication glitch" in the Basal Ganglia, the brain's movement control center. While standard drugs often focus only on dopamine, FECO targets the Endocannabinoid System (ECS), which acts as the "dimmer switch" for motor signals.
1. Re-balancing the Basal Ganglia "Indirect Pathway"
Movement disorders like dyskinesia occur when the "indirect pathway" in the brain becomes overactive or under-sensitive.
GABA Modulation: Cannabinoids in FECO (particularly THC and CBD) stimulate receptors in the Globus Pallidus, a key node in the basal ganglia. This stimulation reduces the reuptake of GABA, the brain’s primary inhibitory neurotransmitter. By increasing GABA "chatter," FECO helps "quiet" the involuntary, jerky movements of dyskinesia.
Glutamate Regulation: Dyskinesia is often driven by an excess of glutamate (the brain's "on" switch). FECO acts as a retrograde messenger, signaling the brain to stop releasing excess glutamate, which prevents the "over-firing" of muscles.
2. The "Full Extract" Advantage (FECO vs. CBD)
While pure CBD is popular, 2026 clinical observations suggest that FECO is superior for movement disorders because of the Entourage Effect:
THC as a Muscle Relaxant: Low-dose THC is a potent anti-spasmodic. In FECO, this effect is balanced by CBD, which prevents the "high" while maintaining the motor-calming benefits.
Terpene Synergy: FECO contains Beta-Caryophyllene, a terpene that acts directly on CB2 receptors. This helps reduce the "neuroinflammation" around dopaminergic neurons, which is a major driver of dyskinesia progression.
FECO vs. Standard Dyskinesia Therapy (2026)
| Feature | Amantadine (Standard) | FECO (Full Extract) |
|---|---|---|
| Primary Mechanism | Glutamate Antagonist. | ECS Modulation (GABA/Glutamate). |
| Movement Type | Targets chorea/jerking. | Targets jerking & muscle rigidity. |
| Side Effects | Hallucinations, blurred vision. | Drowsiness, dry mouth. |
| Secondary Benefit | Minimal. | Improves sleep and anxiety. |
3. Management of "Tardive Dyskinesia" (TD)
For patients with TD (involuntary facial tics or tongue movements from psychiatric meds), FECO offers a unique benefit:
VMAT2 Synergy: In 2026, some clinicians use low-dose FECO alongside VMAT2 inhibitors (like Valbenazine). FECO helps manage the mood-related side effects of these drugs while providing an additional layer of motor control through the TRPV1 "vanilloid" receptors.
4. 2026 "Motor Control" Dosing Protocol
Because dyskinesia is a high-sensitivity condition, the "titration" of FECO is critical to avoid worsening the symptoms:
The "Sweet Spot" Dosing: Movement experts in 2026 have identified a "biphasic" effect—very low doses of FECO calm movement, but very high doses can occasionally cause "cannabis-induced tremors."
Micro-Dosing Syringes: Patients typically use a metered syringe to dispense a dose the size of half a grain of rice (approx. 5–10mg).
Nighttime Loading: Since dyskinesia often stops during sleep but is worse under stress, a slightly larger dose is taken at night to ensure restorative sleep, which "resets" the motor system for the following morning.
2026 Clinical Warning
The Levodopa Interaction: FECO can change how the body processes Levodopa. In 2026, patients are advised to monitor for "Parkinsonian rigidity" if they increase their FECO dose too quickly, as it can occasionally interfere with the effectiveness of dopamine-replacement therapy.
